Inclusion Criteria:

          1. Histologically confirmed diagnosis of neuroblastoma

          2. Must have recurrent or refractory metastatic neuroblastoma following at least two
             prior standard treatment regimen and must have no effective conventional therapy
             existing

          3. Aged between > 1 to 18 years

          4. Life expectancy greater than 3 months

          5. Must have adequate organ function, bone marrow, liver and renal function

          6. Patient assent and parent(s)/legal guardian(s) written informed consent that is
             consistent with local law and ICH-GCP guidelines

        Exclusion Criteria:

          1. Chemotherapy within 4 weeks prior to the start of study treatment

          2. High dose chemotherapy with stem cell transplantation within 3 months prior biological
             therapy or investigational agents within 4 weeks prior to the start of study treatment
             or prior to passing 5 half-lives, i.e. systemic clearance, whatever comes first

          3. Radiotherapy within 30 days before starting study treatment

          4. Prior external beam radiation (EBR) therapy

               -  to more than 25% of the bone marrow

               -  to both kidneys (scatter doses of < 0.5 Gy to a single kidney or radiation to
                  <50% of a single kidney )